Based on ratings from 5 stock analysts, the NeoGenomics Inc stock price is expected to increase by 46.24% in 12 months. This is calculated by using the average 12-month stock price forecast for NeoGenomics Inc. The lowest target is $18.00 and the highest is $26.00. Please note analyst price targets are not guaranteed and could be missed completely.
NeoGenomics Inc has a total of 5 Wall St Analyst ratings. There are 4 buy ratings, 1 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that NeoGenomics Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
mark massaro BTIG | Buy | $21.0 | maintained | Jan 1, 2024 |
daniel brennan TD Cowen | Buy | $19.0 | maintained | Dec 29, 2023 |
derik de bruin Bank of America Securities | Hold | $18.0 | reiterated | Dec 29, 2023 |
michael matson Needham | Buy | $21.0 | maintained | Dec 28, 2023 |
puneet souda Leerink Partners | Buy | $26.0 | maintained | Dec 27, 2023 |
david westenberg Piper Sandler | Buy | $18.0 | rated | Nov 13, 2023 |
tejas savant Morgan Stanley | Hold | $17.0 | maintained | Nov 8, 2023 |
alexander nowak Craig-Hallum | Buy | None | rated | Nov 7, 2023 |
bruce jackson Benchmark Co. | Buy | $18.0 | maintained | Nov 7, 2023 |
matthew sykes Goldman Sachs | Buy | $17.0 | maintained | Oct 20, 2023 |
mason carrico Stephens | Buy | $18.0 | upgraded | Aug 21, 2023 |
andrew cooper Raymond James | Hold | None | downgraded | May 16, 2023 |
jacob johnson Stephens | Buy | $53.0 | maintained | Nov 5, 2021 |
sandy draper Guggenheim | Buy | $54.0 | maintained | May 25, 2021 |
stephen unger Needham | Hold | None | rated | Jan 15, 2021 |
ivy ma Bank of America Securities | Buy | $34.0 | initiatedcoverage | Jun 25, 2020 |
joseph munda First Analysis | Buy | $35.0 | upgraded | Feb 28, 2020 |
tracy marshbanks First Analysis | Buy | None | upgraded | Feb 28, 2020 |
paul knight KeyBanc | Hold | $30.0 | maintained | Feb 27, 2020 |
john hsu Raymond James | Buy | $28.0 | maintained | Oct 30, 2019 |
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
When did it IPO
0
Staff Count
2,100
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Mr. Christopher Michael Smith BSc
Market Cap
$1.83B
In 2023, NEO generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that NEO's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
MORF-USD
$37.68
MRCY-USD
$29.13
EXPI-USD
$11.06
PTCT-USD
$25.91
$33.02
PTON-USD
$4.54